The APACHE-AF is a multicenter, open label, parallel group, randomised clinical trial. Patients will be recruited in academic and regional hospitals in The Netherlands
100 patients with a history of atrial fibrillation and a recent intracerebral haemorrhage during treatment with anticoagulation in whom clinical equipoise exists on the optimal stroke prevention therapy.
Patients will be randomised between apixaban 5 mg twice daily versus antiplatelet therapy or no antithrombotic drugs.
Patients will be recruited in 2.5 years. After recruitment of the 100th patient, follow up continues for 1 year.
The primary endpoint will be the combination of vascular death or non-fatal stroke during follow-up.